Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LRRK2 | Q5S007 | 19/20 | 0.47 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.46 |
| ▸ | SLCO1B1 | Q9Y6L6 | 1/20 | 0.45 |
| ▸ | PTK2 | Q05397 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16985510 | 0.90 | LRRK2 (0.49) | LRRK2SLCO1B1 | |
| SCHEMBL16985442 | 0.85 | LRRK2 (0.51) | LRRK2SLCO1B1 | |
| SCHEMBL18383128 | 0.85 | LRRK2 (0.47) | LRRK2SLCO1B1 | |
| SCHEMBL16985247 | 0.83 | LRRK2 (0.51) | LRRK2SLCO1B1 | |
| SCHEMBL21850164 | 0.81 | LRRK2 (0.47) | LRRK2SLCO1B1 | |
| SCHEMBL18383170 | 0.80 | LRRK2 (0.48) | LRRK2SLCO1B1PTK2 | |
| SCHEMBL18387507 | 0.78 | LRRK2 (0.43) | LRRK2CYP1A2 | |
| SCHEMBL16985574 | 0.78 | LRRK2 (0.44) | LRRK2CYP1A2 | |
| SCHEMBL18383173 | 0.78 | LRRK2 (0.53) | LRRK2SLCO1B1 | |
| SCHEMBL16985507 | 0.77 | LRRK2 (0.49) | LRRK2SLCO1B1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10618901-B2 | LRRK2 inhibitors for the treatment of Parkinson's disease | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2020-04-14 | — | — | US | disclosed |
| EP-3099695-B1 | COMPOUNDS | GLAXOSMITHKLINE IP DEV LTD (GB) | 2020-04-08 | — | — | EP | disclosed |
| US-20170015668-A1 | COMPOUNDS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2017-01-19 | — | — | US | disclosed |
| US-20170015668-A1 | COMPOUNDS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2017-01-19 | — | — | US | disclosed |
| WO-2015113452-A1 | COMPOUNDS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2015-08-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10618901-B2 | LRRK2 inhibitors for the treatment of Parkinson's disease | LRRK2, PARK7, PINK1 | LRRK2 1/4885CYP1A2 4774/4885SLCO1B1 4634/4885 |
| US-20170015668-A1 | COMPOUNDS | LRRK2, PARK7, PINK1 | LRRK2 1/4885CYP1A2 4729/4885SLCO1B1 4733/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.